ArticleRadiation oncology journal2026
Patterns of failure after primary treatment and prognostic factors in stage I, grade 2-3 endometrial cancer.
Article in Radiation oncology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to characterize recurrence patterns and identify prognostic factors in patients with stage I, grade 2-3 endometrioid endometrial cancer. MATERIALS AND
methodsWe retrospectively analyzed 298 patients with 2009 International Federation of Gynecology and Obstetrics stage IA-IB, grade 2-3 endometrioid endometrial cancer treated with curative intent between 2010 and 2020. The primary endpoint was recurrence-free interval (RFI), defined as the time from surgery to documented recurrence or last follow-up. Cox regression analyses were performed to identify prognostic factors. Recursive partitioning analysis (RPA) was used for risk stratification.
resultsWith a median follow-up of 80.1 months, 40 patients (13.4%) experienced recurrence. Distant recurrence was the most common recurrence pattern (n = 28, 9.4%), followed by vaginal recurrence (n = 10, 3.4%), para-aortic recurrence (n = 8, 2.7%) and pelvic recurrence (n = 7, 2.3%). In multivariable analysis, older age (hazard ratio [HR] per year, 1.05; p = 0.004), tumor size ≥4 cm (HR, 2.28; p = 0.027), grade 3 histology (HR, 2.20; p = 0.022), and stage IB disease (HR, 2.31; p = 0.043) were significantly associated with inferior RFI. Estrogen receptor (ER) negativity was associated with inferior RFI in exploratory univariable analysis (HR, 5.10; p < 0.001). An age- and stage-based RPA model classified patients into three groups with significantly different RFI (p < 0.001). Post hoc analysis suggested a higher recurrence proportion among ER-negative patients aged ≤70 years with stage IB disease.
conclusionRecurrence in stage I, grade 2-3 endometrioid endometrial cancer was infrequent, but distant metastasis was the most common recurrence pattern. Conventional clinicopathologic factors provided clinically useful risk stratification, while ER status may offer additional prognostic information in selected subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.